Manufacturing Novartis unveils North Carolina API plant as final piece of $23B US expansion BioSpaceThe new plant will give Novartis end-to-end capabilities centered on North Carolina, where it plans to have five facilities across three sites.Read full story pharminent May 1, 2026 (Last updated: May 1, 2026) BioSpace The new plant will give Novartis end-to-end capabilities centered on North Carolina, where it plans to have five facilities across three sites. Read full story Post navigation Previous: Amgen positions MariTide as potential ‘best monthly’ obesity drugNext: Pfizer, Arvinas join SERD club with Veppanu approval Related Stories Manufacturing Sandoz plans ‘vast and vertically integrated’ supply chain to support 100-biosimilar vision pharminent September 9, 2026 Manufacturing US puts $125m into personalised RNA therapy production pharminent September 2, 2026 Manufacturing Multispecifics are transforming the CDMO development architecture pharminent August 28, 2026